Translational Genomics Research Institute Joins OncLive's Strategic Alliance Partnership

PLAINSBORO, N.J.-- May 24, 2014 -- OncLive^® is pleased to announce that the Translational Genomics Research Institute (TGen) has joined its Strategic Alliance Partnership program.

Through the Strategic Alliance Partnership program, the OncLive editorial and marketing teams will work with TGen to raise awareness of TGen’s cutting-edge translational research programs aimed at unraveling the genetic components of common and complex diseases.

TGen is an industry-leading non-profit research organization that is focused on developing earlier diagnostics and smarter treatments for patients with diseases such as cancer, neurological disorders and diabetes.

Formed in June 2002, TGen’s multidisciplinary research teams work to translate basic scientific discoveries into clinical applications and use cutting-edge technology to analyze the human genome to identify the genes that play a role in disease development and progression.

TGen researchers are currently involved in a variety of phase I and II clinical trials across a number of cancer types, with plans to further develop cancer-specific divisions in pancreatic cancer, breast cancer, leukemia, prostate cancer, and melanoma.

“The name TGen is synonymous with ground-breaking research and insights in the rapidly evolving field of personalized medicine. The researchers and clinicians associated with TGen are pioneers in translating genetic information and breakthroughs into new diagnostic tests and innovative therapies to battle cancer and other life-threatening and debilitating diseases,” said Mike Hennessy, Jr., vice president of OncLive. “We are excited to be working with this respected research group and look forward to a productive partnership.”

To date, more than 20 cancer centers, nursing schools, and other groups have joined OncLive’s Strategic Alliance Partnership program.

To learn more about OncLive^®, visit www.OncLive.com.

About OncLive^®

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive^® and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research, and education. To learn more, please visit www.OncLive.com.

About TGen

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Contact:

For OncLive

Courtney Dysart, 267-932-8760 Ext. 300

courtney@hornercom.com